Table 3.
Antimicrobial resistance of ESBL and non-ESBL producing Klebsiella spp in Dar es Salaam, Tanzania (n = 138)
| Antibiotic | Resistance n (%) |
ESBL- Producing n = 68 |
Non-ESBL producing n = 64 |
P-value* |
|---|---|---|---|---|
| Cefotaxime | 87(65.9%) | 68(100) | 19(29.7) | < 0.001 |
| Ceftazidime | 87(65.9%) | 68(100) | 19(29.7) | < 0.001 |
| Ampicillin | 130(98.5%) | 67(98.5) | 63(98.4) | 0.9 |
| Amoxicillin/ clavulanic acid |
103(78.0%) | 57(83.8) | 46(71.9) | 0.09 |
| Imipenem | 9(6.8%) | 6(8.8) | 3(4.7) | 0.2 |
| Amikacin | 28(21.2%) | 17(25.0) | 11(17.2) | 0.2 |
| Gentamicin | 38(28.8%) | 26(38.2) | 12(18.8) | 0.008 |
| Nalidixic acid | 65(49.2%) | 45(66.2) | 20(31.2) | < 0.001 |
| Ciprofloxacin | 25(18.9%) | 17(25.0) | 18(28.1) | 0.04 |
| Nitrofurantoin | 24(18.2%) | 14(20.6) | 11(17.2) | 0.5 |
| Cotrimoxazole | 109(82.6%) | 63(92.6) | 46(71.9) | 0.001 |
| Multi drug resistance | 79(59.8%) | 56(82.4) | 23(35.9) | < 0.001 |
*P value is for a comparison of resistance among ESBL-producers with that among non-Producers.